|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500109684 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-23 18:35:04 |
|
注册时间: Date of Registration: |
2025-09-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
舌黏膜补片联合后壁重建输尿管扩大成形术在输尿管狭窄修复重建中的临床应用研究 |
|
Public title: |
Clinical Application Study of Posterior Augmented Anastomotic Lingual Mucosal Onlay Graft Ureteroplasty in the Repair of Ureteral Strictures |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
舌黏膜补片联合后壁重建输尿管扩大成形术在输尿管狭窄修复重建中的临床应用研究 |
|
Scientific title: |
Clinical Application Study of Posterior Augmented Anastomotic Lingual Mucosal Onlay Graft Ureteroplasty in the Repair of Ureteral Strictures |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
许康祥 |
研究负责人: |
李兵 |
|
Applicant: |
Kangxiang Xu |
Study leader: |
Bing Li |
|
申请注册联系人电话: Applicant telephone: |
+86 150 7908 6950 |
研究负责人电话: Study leader's telephone: |
+86 138 7136 1899 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xkx010601@163.com |
研究负责人电子邮件: Study leader's E-mail: |
bingli2023@whu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市武昌区东湖路169号 |
研究负责人通讯地址: |
湖北省武汉市武昌区东湖路169号 |
|
Applicant address: |
No.169 Donghu Road, Wuchang District, Wuhan City, Hubei Province, China |
Study leader's address: |
No.169 Donghu Road, Wuchang District, Wuhan City, Hubei Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
武汉大学中南医院 |
||
|
Applicant's institution: |
Zhongnan Hospital of Wuhan University |
||
|
研究负责人所在单位: |
武汉大学中南医院 |
||
|
Affiliation of the Leader: |
Zhongnan Hospital of Wuhan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
临研伦[2025196K] |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
武汉大学中南医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee, Zhongnan Hospital of Wuhan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-30 00:00:00 |
||
|
伦理委员会联系人: |
郑磊 |
||
|
Contact Name of the ethic committee: |
Lei Zheng |
||
|
伦理委员会联系地址: |
湖北省武汉市武昌区东湖路169号 |
||
|
Contact Address of the ethic committee: |
No.169 Donghu Road, Wuchang District, Wuhan City, Hubei Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 6781 2787 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
znyyll@126.com |
|
研究实施负责(组长)单位: |
武汉大学中南医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongnan Hospital of Wuhan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市武昌区东湖路169号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.169 Donghu Road, Wuchang District, Wuhan City, Hubei Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
武汉大学中南医院人才项目—脱细胞基质材料-自体组织在尿路修复中的基础和临床应用研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
The basic and clinical application of talent project-acellular matrix material-autologous tissue in urinary tract repair in Zhongnan Hospital of Wuhan University |
||||||||||||||||||||||
|
Target disease: |
Obstructive nephropathy |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例研究 |
||||||||||||||||||||||
|
Study design: |
Case study |
||||||||||||||||||||||
|
研究目的: |
发现梗阻性肾病早期肾损伤的生物标记物,为临床及时干预治疗提供指导意义。 |
||||||||||||||||||||||
|
Objectives of Study: |
The discovery of biomarkers of early renal injury in obstructive nephropathy provides guidance for timely clinical intervention. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄≥16岁; 2.根据既往病史、影像学检查等明确诊断为良性输尿管狭窄; 3.已接受舌黏膜补片联合后壁重建输尿管扩大成形术治疗; 4.术前术后均有完整的影像学及临床随访资料; 5.患者及家属知情同意,并愿意配合临床资料使用。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 16 years; 2. Confirmed diagnosis of benign ureteral stricture based on medical history, imaging studies, etc.; 3. Previously treated with lingual mucosal patch graft combined with posterior wall reconstruction ureteroplasty; 4. Complete pre- and post-operative imaging and clinical follow-up documentation available; 5. Informed consent obtained from patient and family, with willingness to permit use of clinical data. |
||||||||||||||||||||||
|
排除标准: |
1.合并泌尿系统恶性肿瘤或活动性泌尿道感染者; 2.伴有严重心肺功能障碍或其他不能耐受手术的全身性疾病; 3.既往接受过复杂的肠代输尿管术或自体肾移植术者; 4.随访资料不全或失访者; 5.存在严重口腔疾病不适合舌黏膜取材者; 6.其他导致患者不适合参与本研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with concurrent malignant tumours of the urinary system or active urinary tract infections; 2. Patients with severe cardiopulmonary dysfunction or other systemic conditions rendering them unable to tolerate surgery; 3. Patients who have previously undergone complex intestinal ureteral reconstruction or autologous kidney transplantation; 4. Patients with incomplete follow-up records or who are lost to follow-up; 5. Patients with severe oral diseases rendering them unsuitable for tongue mucosa sampling; 6. Other circumstances rendering the patient unsuitable for participation in this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-31 00:00:00至 To 2027-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-09-30 00:00:00 至 To 2027-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成6个月内,通过联系邮箱xkx010601@163.com共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within 6 months of the completion of the trial, it will be shared by contacting chaishuai0605@126.com. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |